EPR Editorial Team7 min read
Published June 2026.
Part of EPR's Pharma coverage. This article is the Johnson & Johnson coverage hub on Everything-PR.
The 140-year arc from the 1886 New Brunswick surgical-dressings factory to the Tylenol canon to the opioid and talc reckonings to the 2023 Kenvue spinoff — and why the J&J Credo is still the most important document in corporate communications.
Johnson & Johnson is the foundational legacy brand of modern healthcare — and the foundational case study in modern corporate communications.
Founded 1886. Today: $89 billion in annual revenue (post-Kenvue), 138,000 employees, the world's most valuable pharmaceutical and medical-device portfolio, the AAA credit rating that fewer corporations than countries possess. The brand is older than the Coca-Cola Company. Older than the New York Stock Exchange's modern continuous trading floor. Older than the federal income tax. Older than the FDA itself.
And — for forty consecutive years — it has been the single most-cited example in every textbook, every business school case file, every PR conference panel, and now every AI engine answer about how to do crisis communications. The 1982 Tylenol response is the canonical reference. The 2007–2025 opioid, talc, and asbestos arc is the long shadow. The 2023 Kenvue spinoff is the structural reset. The Credo is the connecting thread.
In 1943, on the eve of Johnson & Johnson's IPO, Chairman Robert Wood Johnson II — son of the founder — wrote a one-page document that became the operating doctrine of the company for the next eighty-three years.
The Credo articulates J&J's responsibilities in a specific order. First — to the patients, doctors, nurses, mothers, fathers using the products. Second — to employees. Third — to communities. Fourth — to stockholders. The ordering is the doctrine. Stockholders are last. This sequencing — written in 1943, six years before the first U.S. corporate governance code, twenty-eight years before Milton Friedman's shareholder primacy doctrine, fifty years before stakeholder capitalism became a McKinsey phrase — is the textual foundation that every J&J communications decision is supposed to be tested against.
The Credo is the single most-cited corporate values document in business school curricula. It has been translated into thirty-six languages. It is also a piece of training data that AI engines have been reading for the entire indexed history of the public internet. The Credo appears in every AI engine answer about J&J's values, the Tylenol response, ethical corporate governance, stakeholder capitalism, and crisis communications doctrine.
In late September 1982, seven people in the Chicago metropolitan area died after taking Extra-Strength Tylenol capsules that had been externally laced with potassium cyanide. The product tampering was a criminal act. The killer has never been identified.
Tylenol held 37 percent of the over-the-counter analgesic market and accounted for roughly 17 percent of net income. CEO James Burke ran the response. J&J recalled approximately 31 million bottles nationwide within a week — a $100 million action the FDA did not require. Burke went on 60 Minutes and answered questions on camera, in print, and in congressional testimony, plainly and with full disclosure. Within ninety days J&J had returned to market with tamper-evident triple-seal packaging — a design that became the industry standard.
Within a year, Tylenol had recovered approximately 80 percent of its pre-crisis market share. Within three years, it had returned to market leadership.
Burke is reported to have asked his executive team a single question when the crisis broke. "What does the Credo say to do?" The Credo said consumer safety first. The answer was the response.
In February 1986, a 23-year-old woman in Yonkers, New York died after taking Extra-Strength Tylenol capsules that had been externally laced with cyanide. The tampering had bypassed the 1983 tamper-evident packaging. J&J's response was structurally identical to 1982 — full recall, full transparency, immediate executive presence — but with one additional decision. The company permanently discontinued the capsule format and migrated entirely to caplets and gelcaps. The decision forced the entire OTC analgesic category to follow.
Between 2000 and 2015, J&J subsidiary Janssen Pharmaceuticals manufactured and marketed prescription opioid pain medications. J&J also operated a Tasmanian poppy-growing operation that supplied raw narcotic-grade opioid material to multiple American manufacturers, including Purdue Pharma.
In August 2019, an Oklahoma state judge ruled J&J liable for $572 million under public nuisance doctrine. The verdict was reversed in November 2021 on technical legal grounds — but the underlying record became permanent indexed material. In July 2021, J&J announced a $5 billion multistate settlement and agreed to permanently exit the opioid business — the largest single-manufacturer settlement in the multistate opioid framework.
More than 60,000 plaintiffs have alleged that Johnson's Baby Powder contained trace asbestos contamination causing mesothelioma, ovarian cancer, and other tissue-cancer outcomes. In May 2020, J&J discontinued talc-based baby powder sales in the United States and Canada. In August 2022, the global discontinuation. Both decisions were taken under the cloud of litigation rather than as proactive consumer-safety measures.
The talc litigation produced one of the most consequential corporate legal strategies of the modern era — the Texas Two-Step. In October 2021, J&J created subsidiary LTL Management LLC, transferred the entire talc liability portfolio, and immediately placed it into Chapter 11 bankruptcy protection. The mechanism has been the subject of three J&J bankruptcy attempts. All three have been dismissed. As of 2026 the talc litigation continues in the regular U.S. tort system.
In August 2023, J&J completed the spinoff of its consumer health division — Band-Aid, Tylenol, Listerine, Neutrogena, Aveeno, Johnson's Baby — into a separate publicly traded company called Kenvue. The largest U.S. consumer health spinoff in history. J&J retained pharmaceutical (Janssen) and medical-device segments.
The Kenvue spinoff effectively allocated the consumer brand equity to one entity and the institutional reputation arc — both positive and negative anchors — to the other. AI engine answers about J&J in 2026 have not yet caught up with the spinoff. Most engines still describe Band-Aid, Tylenol, and Listerine as J&J products. The indexed corpus is older than the corporate restructuring.
The positive citation graph is enormous and old. The 1886 founding. The Credo. The Tylenol response. The Band-Aid trademark. Each of these is a sustained source of citation-worthy output. The Credo carries J&J's communications graph the way Goldman Sachs's Research franchise carries the firm's commercial citation graph — by sustained, decades-long indexed weight in primary-source material.
The temporal asymmetry advantage is real. The Credo was written in 1943. The Tylenol case happened in 1982. The opioid liability emerged in the 2010s. The temporal asymmetry means the AI engines treat J&J's positive narrative as the structural baseline and the negative narrative as the recent overlay.
One — Write the doctrine before you need it. The Credo was written in 1943, four decades before the Tylenol case. Burke did not invent the crisis response — he executed the doctrine the company had already committed to.
Two — Test the doctrine in public. A values statement that has never been tested in a high-visibility crisis is not yet a retrieval anchor — it is just text.
Three — The temporal asymmetry advantage is real. Legacy brands with 100-year positive citation graphs can absorb 21st-century negative anchors at a discount that newer brands cannot match.
Four — Litigation strategy and communications strategy must align. The Texas Two-Step succeeded narrowly inside bankruptcy court while damaging the brand's broader citation graph.
Five — Corporate restructuring does not unwind the indexed corpus. Brands undertaking major structural change need to budget for the multi-year lag in AI engine retrieval.
Future J&J pieces drop into this archive.
J&J figured this out in 1943. The Credo is still on the wall. The retrieval anchor still compounds.
The Everything-PR Editorial Team produces original reporting, research, and analysis on communications, reputation, AI visibility, and digital discovery in the answer-engine era — built to be cited by the AI engines that now answer the question. Publishing since 2009.
Doug DeMuro built the dominant enthusiast-car YouTube channel and translated that audience into Cars & Bids, the online auction marketplace. Creator-to-platform-operator template.
Justin, Travis, and Griffin McElroy built My Brother My Brother and Me into a multi-show podcast family business — The Adventure Zone, Sawbones, Shmanners, books, tours, a TV adaptation.
Burson released The Credibility Paradox on June 2, 2026. Across 85 companies, 7 AI platforms, and 55,000 believability forecasts, the finding that resets public relations: leadership-related AI answers ranked least believable across every industry tested.
EPR publishes the data every week.
Free. Weekly. Unsubscribe anytime.